|
1
|
Bikle D: Nonclassic actions of vitamin D.
J Clin Endocrinol Metab. 94:26–34. 2009. View Article : Google Scholar :
|
|
2
|
Holick MF: Vitamin D: Its role in cancer
prevention and treatment. Prog Biophys Mol Biol. 92:49–59. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Holick MF: Vitamin D deficiency. N Engl J
Med. 357:266–281. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Plum LA and DeLuca HF: Vitamin D, disease
and therapeutic opportunities. Nat Rev Drug Discov. 9:941–955.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hewison M: Vitamin D and the immune
system: new perspectives on an old theme. Endocrinol Metab Clin
North Am. 39:365–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Etten E, Stoffels K, Gysemans C,
Mathieu C and Overbergh L: Regulation of vitamin D homeostasis:
implications for the immune system. Nutr Rev. 66(Suppl 2):
S125–S134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holick MF: Vitamin D: importance in the
prevention of cancers, type 1 diabetes, heart disease, and
osteoporosis. Am J Clin Nutr. 79:362–371. 2004.PubMed/NCBI
|
|
8
|
Holick MF: Vitamin D and sunlight:
strategies for cancer prevention and other health benefits. Clin J
Am Soc Nephrol. 3:1548–1554. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spina CS, Tangpricha V, Uskokovic M,
Adorinic L, Maehr H and Holick MF: Vitamin D and cancer. Anticancer
Res. 26:2515–2524. 2006.PubMed/NCBI
|
|
10
|
Walsh JE, Clark AM, Day TA, Gillespie MB
and Young MR: Use of α,25-dihydroxyvitamin D3 treatment
to stimulate immune infiltration into head and neck squamous cell
carcinoma. Hum Immunol. 71:659–665. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Welsh J: Cellular and molecular effects of
vitamin D on carcinogenesis. Arch Biochem Biophys. 523:107–114.
2012. View Article : Google Scholar :
|
|
12
|
Mehta RG, Hussain EA, Mehta RR and Das
Gupta TK: Chemoprevention of mammary carcinogenesis by
1α-hydroxyvitamin D5, a synthetic analog of vitamin D.
Mutat Res. 523–524:253–264. 2003. View Article : Google Scholar
|
|
13
|
Peng X, Hawthorne M, Vaishnav A, St-Arnaud
R and Mehta RG: 25-Hydroxyvitamin D3 is a natural
chemopreventive agent against carcinogen induced precancerous
lesions in mouse mammary gland organ culture. Breast Cancer Res
Treat. 113:31–41. 2009. View Article : Google Scholar :
|
|
14
|
Pommergaard HC, Burcharth J, Rosenberg J
and Raskov H: Chemoprevention with acetylsalicylic acid, vitamin D
and calcium reduces risk of carcinogen-induced lung tumors.
Anticancer Res. 33:4767–4770. 2013.PubMed/NCBI
|
|
15
|
Fedirko V, Bostick RM, Long Q, et al:
Effects of supplemental vitamin D and calcium on oxidative DNA
damage marker in normal colorectal mucosa: a randomized clinical
trial. Cancer Epidemiol Biomarkers Prev. 19:280–291. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Slominski AT, Kim TK, Li W, Yi AK,
Postlethwaite A and Tuckey RC: The role of CYP11A1 in the
production of vitamin D metabolites and their role in the
regulation of epidermal functions. J Steroid Biochem Mol Biol.
144PA:28–39. 2014. View Article : Google Scholar
|
|
17
|
Slominski AT, Janjetovic Z, Kim TK, et al:
Novel vitamin d hydroxyderivatives inhibit melanoma growth and show
differential effects on normal melanocytes. Anticancer Res.
32:3733–3742. 2012.PubMed/NCBI
|
|
18
|
Bikle DD: Vitamin D: an ancient hormone.
Exp Dermatol. 20:7–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bikle DD: Vitamin D and the skin:
physiology and pathophysiology. Rev Endocr Metab Disord. 13:3–19.
2012. View Article : Google Scholar
|
|
20
|
Thorne J and Campbell MJ: The vitamin D
receptor in cancer. Proc Nutr Soc. 67:115–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brożyna AA, Jozwicki W, Janjetovic Z and
Slominski AT: Expression of vitamin D receptor decreases during
progression of pigmented skin lesions. Hum Pathol. 42:618–631.
2011. View Article : Google Scholar
|
|
22
|
Anderson MG, Nakane M, Ruan X, Kroeger PE
and Wu-Wong JR: Expression of VDR and CYP24A1 mRNA in human tumors.
Cancer Chemother Pharmacol. 57:234–240. 2006. View Article : Google Scholar
|
|
23
|
Brożyna AA, Jóźwicki W and Slominski AT:
Decreased VDR expression in cutaneous melanomas as marker of tumor
progression: new data and analyses. Anticancer Res. 34:2735–2744.
2014.
|
|
24
|
Matusiak D, Murillo G, Carroll RE, Mehta
RG and Benya RV: Expression of vitamin D receptor and
25-hydroxyvitamin D3-1α-hydroxylase in normal and malignant human
colon. Cancer Epidemiol Biomarkers Prev. 14:2370–2376. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Menezes RJ, Cheney RT, Husain A, et al:
Vitamin D receptor expression in normal, premalignant, and
malignant human lung tissue. Cancer Epidemiol Biomarkers Prev.
17:1104–1110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu Y, Li J and Zhang Y: Polymorphisms in
the vitamin D receptor gene and the lung cancer risk. Tumour Biol.
35:1323–1330. 2014. View Article : Google Scholar
|
|
27
|
Randerson-Moor JA, Taylor JC, Elliott F,
et al: Vitamin D receptor gene polymorphisms, serum
25-hydroxyvitamin D levels, and melanoma: UK case-control
comparisons and a meta-analysis of published VDR data. Eur J
Cancer. 45:3271–3281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shan JL, Dai N, Yang XQ, et al: FokI
polymorphism in vitamin D receptor gene and risk of breast cancer
among Caucasian women. Tumour Biol. 35:3503–3508. 2014. View Article : Google Scholar
|
|
29
|
Li S, Xu H, Li SC, Qi XQ and Sun WJ:
Vitamin D receptor rs2228570 polymorphism and susceptibly to
ovarian cancer: a meta-analysis. Tumour Biol. 35:1319–1322. 2014.
View Article : Google Scholar
|
|
30
|
Liu Y, Li C, Chen P, et al: Polymorphisms
in the vitamin D receptor (VDR) and the risk of ovarian cancer: a
meta-analysis. PLoS One. 8:e667162013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu H, Li S, Qiu JQ, Gao XL, Zhang P and
Yang YX: The VDR gene Fok I polymorphism and ovarian cancer risk.
Tumour Biol. 34:3309–3316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zehnder D, Bland R, Walker EA, et al:
Expression of 25-hydroxyvitamin D3-1α-hydroxylase in the
human kidney. J Am Soc Nephrol. 10:2465–2473. 1999.PubMed/NCBI
|
|
33
|
Slominski AT, Kim TK, Shehabi HZ, et al:
In vivo evidence for a novel pathway of vitamin D3
metabolism initiated by P450scc and modified by CYP27B1. FASEB J.
26:3901–3915. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Slominski AT, Kim TK, Shehabi HZ, et al:
In vivo production of novel vitamin D2 hydroxy-derivatives by human
placentas, epidermal keratinocytes, Caco-2 colon cells and the
adrenal gland. Mol Cell Endocrinol. 383:181–192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Radermacher J, Diesel B, Seifert M, et al:
Expression analysis of CYP27B1 in tumor biopsies and cell cultures.
Anticancer Res. 26:2683–2686. 2006.PubMed/NCBI
|
|
36
|
Tangpricha V, Flanagan JN, Whitlatch LW,
et al: 25-hydroxyvitamin D-1α-hydroxylase in normal and malignant
colon tissue. Lancet. 357:1673–1674. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lopes N, Sousa B, Martins D, et al:
Alterations in Vitamin D signalling and metabolic pathways in
breast cancer progression: a study of VDR, CYP27B1 and CYP24A1
expression in benign and malignant breast lesions Vitamin D
pathways unbalanced in breast lesions. BMC Cancer. 10:4832010.
View Article : Google Scholar :
|
|
38
|
Evans KN, Taylor H, Zehnder D, et al:
Increased expression of 25-hydroxyvitamin D-1α-hydroxylase in
dysgerminomas: a novel form of humoral hypercalcemia of malignancy.
Am J Pathol. 165:807–813. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takeyama K and Kato S: The vitamin D3
1α-hydroxylase gene and its regulation by active vitamin D3. Biosci
Biotechnol Biochem. 75:208–213. 2011. View Article : Google Scholar
|
|
40
|
Garland CF, Comstock GW, Garland FC,
Helsing KJ, Shaw EK and Gorham ED: Serum 25-hydroxyvitamin D and
colon cancer: eight-year prospective study. Lancet. 2:1176–1178.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hanchette CL and Schwartz GG: Geographic
patterns of prostate cancer mortality. Evidence for a protective
effect of ultraviolet radiation. Cancer. 70:2861–2869. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hiatt RA, Krieger N, Lobaugh B, Drezner
MK, Vogelman JH and Orentreich N: Prediagnostic serum vitamin D and
breast cancer. J Natl Cancer Inst. 90:461–463. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
International Agency for Research on
Cancer. Vitamin D and Cancer. 5. IARC; Lyon: 2008
|
|
44
|
Petrioli R, Pascucci A, Francini E, et al:
Weekly high-dose calcitriol and docetaxel in patients with
metastatic hormone-refractory prostate cancer previously exposed to
docetaxel. BJU Int. 100:775–779. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Walentowicz-Sadlecka M, Grabiec M,
Sadlecki P, et al: 25(OH) D3 in patients with ovarian cancer and
its correlation with survival. Clin Biochem. 45:1568–1572. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Redaniel MT, Gardner MP, Martin RM and
Jeffreys M: The association of vitamin D supplementation with the
risk of cancer in postmenopausal women. Cancer Causes Control.
25:267–271. 2014. View Article : Google Scholar
|
|
47
|
Tavassoli FA and Devilee P: World Health
Organization Classification of Tumours. Pathology and Genetics of
Tumours of the Breast and Female Genital Organs. IARC Press; Lyon:
2003
|
|
48
|
Brożyna AA, Jóźwicki W, Janjetovic Z and
Slominski AT: Expression of the vitamin D-activating enzyme
1α-hydroxylase (CYP27B1) decreases during melanoma progression. Hum
Pathol. 44:374–387. 2013. View Article : Google Scholar
|
|
49
|
Janjetovic Z, Brozyna AA, Tuckey RC, et
al: High basal NF-κB activity in nonpigmented melanoma cells is
associated with an enhanced sensitivity to vitamin D3 derivatives.
Br J Cancer. 105:1874–1884. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jozwicki W, Windorbska W, Brozyna AA, et
al: The analysis of receptor-binding cancer antigen expressed on
SiSo cells (RCAS1) immunoreactivity within the microenvironment of
the ovarian cancer lesion relative to the applied therapeutic
strategy. Cell Tissue Res. 345:405–414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hwang WT, Adams SF, Tahirovic E, Hagemann
IS and Coukos G: Prognostic significance of tumor-infiltrating T
cells in ovarian cancer: a meta-analysis. Gynecol Oncol.
124:192–198. 2012. View Article : Google Scholar :
|
|
52
|
Webb JR, Milne K, Watson P, Deleeuw RJ and
Nelson BH: Tumor-infiltrating lymphocytes expressing the tissue
resident memory marker CD103 are associated with increased survival
in high-grade serous ovarian cancer. Clin Cancer Res. 20:434–444.
2014. View Article : Google Scholar
|
|
53
|
Holick MF: Vitamin D: evolutionary,
physiological and health perspectives. Curr Drug Targets. 12:4–18.
2011. View Article : Google Scholar
|
|
54
|
Bises G, Kallay E, Weiland T, et al:
25-hydroxyvitamin D3-1α-hydroxylase expression in normal
and malignant human colon. J Histochem Cytochem. 52:985–989. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Clinckspoor I, Hauben E, Verlinden L, et
al: Altered expression of key players in vitamin D metabolism and
signaling in malignant and benign thyroid tumors. J Histochem
Cytochem. 60:502–511. 2012.PubMed/NCBI
|
|
56
|
Hsu JY, Feldman D, McNeal JE and Peehl DM:
Reduced 1α-hydroxylase activity in human prostate cancer cells
correlates with decreased susceptibility to 25-hydroxyvitamin
D3-induced growth inhibition. Cancer Res. 61:2852–2856.
2001.PubMed/NCBI
|
|
57
|
Friedrich M, Diesing D, Cordes T, et al:
Analysis of 25-hydroxyvitamin D3-1α-hydroxylase in
normal and malignant breast tissue. Anticancer Res. 26:2615–2620.
2006.PubMed/NCBI
|
|
58
|
Agic A, Xu H, Altgassen C, et al: Relative
expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D
1α-hydroxylase, vitamin D 24-hydroxylase, and vitamin D
25-hydroxylase in endometriosis and gynecologic cancers. Reprod
Sci. 14:486–497. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fischer D, Thome M, Becker S, et al:
25-Hydroxyvitamin D3 1α-hydroxylase splice variants in
benign and malignant ovarian cell lines and tissue. Anticancer Res.
29:3627–3633. 2009.PubMed/NCBI
|
|
60
|
Reichrath J, Rafi L, Rech M, et al:
Analysis of the vitamin D system in cutaneous squamous cell
carcinomas. J Cutan Pathol. 31:224–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Urbschat A, Paulus P, von Quernheim QF, et
al: Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal
cell carcinoma. Eur J Clin Invest. 43:1282–1290. 2012. View Article : Google Scholar
|
|
62
|
Flanagan JN, Wang L, Tangpricha V,
Reichrath J, Chen TC and Holick MF: Regulation of the
25-hydroxyvitamin D-1α-hydroxylase gene and its splice variant.
Recent Results Cancer Res. 164:157–167. 2003. View Article : Google Scholar
|
|
63
|
Wu S, Ren S, Nguyen L, Adams JS and
Hewison M: Splice variants of the CYP27b1 gene and the regulation
of 1,25-dihydroxyvitamin D3 production. Endocrinology.
148:3410–3418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fischer D, Seifert M, Becker S, et al:
25-Hydroxyvitamin D3 1α-hydroxylase splice variants in
breast cell lines MCF-7 and MCF-10. Cancer Genomics Proteomics.
4:295–300. 2007.PubMed/NCBI
|
